坦索罗辛、索利那新治疗双J管致膀胱刺激症状的疗效观察

Efficacy of tamsulosin and/or solifenacin for overactive bladder symptoms caused by double-J ureteral stent

目的:通过前瞻性研究方法探讨单用或联用坦索罗辛、索利那新治疗双J管所致膀胱刺激症状的疗效。方法:75例患者随机分入A、B、C、D组,A组19例,给予坦索罗辛口服治疗;B组18例,给予索利那新口服治疗;C组22例,给予坦索罗辛+索利那新口服治疗;D组16例,仅给予术后常规治疗。通过OAB症状评分问卷了解膀胱刺激症状严重程度,详细记录肉眼血尿、泌尿系感染及尿痛的发生率。结果:口服坦索罗辛或索利那新能够明显减轻双J管所引起的膀胱刺激症状,坦索罗辛的治疗作用强于索利那新,且两药联用疗效优于其中任何一种单药的疗效。坦索罗辛、索利那新及两药联用无法降低患者血尿及泌尿系感染的发生率,但是却可以降低尿痛的发生率,且两药联用的疗效强于单药的疗效。结论:坦索罗辛及索利那新能够有效地减轻双J管引起的膀胱刺激症状,并减少尿痛的发生,且两药联用疗效优于单药的使用。

Objective To explore the efficacy of tamsulosin and for solitenaein in the treatment of overactive bladder symptoms caused by double-J ureteral stent via a prospective control study. Methods 75 patients were randomly derided into group A, B, C, or D. A total of 19 patients received tamsulosin alone （group A）, 18 patients received solifenacin alone （group B）, 22 patients receievd combination therapy with two agents （group C）, and 16 patients received routine postoperative treatment （group D）. The severity of overactive bladder symptoms was determined by the questionnaires on OAB symptom scores. The incidem：e rates of hematuria, urinary tract infetion, and painful urination were noted in detail. Results Tamsulosin alone relieved overactive bladder symptoms more significantly than solifenacin alone, and the efficacy of combination therapy with tamsulosin and solitenaein was better than that of monotherapy with tamsulosin or solifenaein. Tamsulosin or solitenac.in alone, or combination therapy with the two agents did not reduce the incidence rates of hematuria and urinary tract infection, but could decline the rate of painful urination; and the efficacy of combination therapy was better than that of a single agent. Conclusions Tamsulosin or solifenaein can effectively relieve overactive bladder symploms caused by double-J ureteral stents and reduce the incidence rate of painful urination. The efficacy of combination therapy with the two agents is better than that of a single agent.